baber/WOPTO huggingface dataset:
Patent JP-2583626-B2 (JP)
IPC: B26D1/46
Filed: 1989-01-23
Granted: 1997-02-19
Abstract: PCT No. PCT/FI89/00011 Sec. 371 Date Sep. 11, 1990 Sec. 102(e) Date Sep. 11, 1990 PCT Filed Jan. 23, 1989 PCT Pub. No. WO89/07731 PCT Pub. Date Aug. 24, 1989.The invention relates to an apparatus for the formation of an insulating material ply, e.g. in the manufacture of insulating chutes. The object is to provide a continuous insulating material ply (17) of a predetermined thickness. A primary ply (14) of surplus thickness is first sawn out of an insulating material roll (1) by rotating the insulating wool roll against the edge of a band saw, and this primary ply (14) is fed to another ply-cutting saw (16) which saws the primary ply into the final ply (17) with the predetermined thickness. The surplus from the primary ply (14) is collected on a drum (19) provided in connection with the ply-cutting saw (16) to form an intermediate storage. When the insulating material (roll) run out, the sawing of the final ply (17) is continued from the intermediate storage without interruption until the leading edge of a new opened insulating material roll (1) reaches the ply-cutting saw (16).
Patent JP-3273608-B2 (JP)
IPC: A61K47/48
Filed: 1990-01-23
Granted: 2002-04-08
Abstract: A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active drug in the presence of the activator. In the preferred embodiment, the targeting moiety, the activator, and the prodrug demonstrate little or no immunogenecity in the animal being treated. The targeting moiety is relatively specific for binding to the target tissue than to non-target tissue. The activator is not found or present in only small amounts in circulation or in non-target tissue, does not have a substrate for its activity in circulation or in non-target tissue, can be linked to the targeting moiety, and is capable of converting the prodrug to an active drug. The prodrug is selected for its ability to exert a cytotoxic activity on the target tissue after conversion by the activator.
Patent JP-3706389-B2 (JP)
IPC: E04B1/58
Filed: 1995-05-17
Granted: 2005-10-12
Abstract: PCT No. PCT/SE95/00550 Sec. 371 Date Jan. 6, 1997 Sec. 102(e) Date Jan. 6, 1997 PCT Filed May 17, 1995 PCT Pub. No. WO96/01376 PCT Pub. Date Jan. 18, 1996An arrangement for a connection device for providing detachable connection of pairs of elements through a displaceable piston capable of actuation by spring force. The spring is accommodated internally within a cavity in a connection sleeve with a retaining end of the piston and is capable of being locked in a connection position by a locking screw that interacts with an inclined tensioning surface in the piston and with a gripping device projecting from the cavity on a connecting end of the piston. The gripping device faces outward from the cavity. A lock is present between the sleeve and the piston to limit the projection of the piston from the internal cavity of the sleeve.
Patent JP-3336018-B2 (JP)
IPC: F01M13/04
Filed: 1998-06-25
Granted: 2002-10-21
Abstract: An arrangement for use in separating a hydrophobic liquid aerosol phase, from a gas stream, during filtration of engine crankcase gases by passage of the gases into a first stage coalescer filter and then into a pleated upstream surface of a second stage filter; said arrangement comprising: a first stage coalescer filter including a coalescer housing framework defining: a non-porous, outer peripheral wall with first and second, opposite, open ends and a flow passageway extending between the open ends; the first stage coalescer filter including a non-woven, non-pleated, fibrous bundle sealed in the coalescer housing framework and extending across the flow passageway; the non-woven fibrous bundle being positioned between an upstream open screen which extends across the first open end; and, a downstream open screen which extends across the second open end; the non-woven fibrous bundle having a first upstream surface area; and a second stage filter element comprising pleated media and having a pleated upstream surface for receiving gas flow from the first stage coalescer filter; the pleated upstream surface having a second upstream surface area; the first upstream surfaces are being within the range of 0.1 %-10% of the second upstream surface area. <IMAGE>
Patent JP-3152398-B2 (JP)
IPC: A61F13/00
Filed: 1990-04-03
Granted: 2001-04-03
Abstract: A wound dressing includes a cover membrane comprising a semi-permeable material with an adhesive-coated skin contact surface. An opening is formed in an interior portion of the membrane. An intermediate layer of material may be placed between the wound and the membrane contact surface for either absorbing fluids from the wound, e.g. with a hydrocolloid or hydrophilic material, or for passing such fluids to the opening with a synthetic material, e.g. rayon. A tube includes a proximate end fluidically communicating with the wound through the membrane opening. A distal end of the tube is adapted for connection to a suction source for draining the wound or fluid source for introducing liquid medication to the wound. Both evacuation and introduction can be either active or passive. A wound treatment method is also disclosed.
Patent JP-3306073-B2 (JP)
IPC: C12Q1/68
Filed: 1997-07-24
Granted: 2002-07-24
Abstract: A novel class of compounds, known as peptide nucleic acids, bind complementary DNA and RNA strands more strongly than a corresponding DNA strand, and exhibit increased sequence specificity and solubility. The peptide nucleic acids comprise ligands selected from a group consisting of naturally-occurring nucleobases and non-naturally-occurring nucleobases attached to a polyamide backbone, and contain C1-C8 alkylamine side chains. Methods of enhancing the solubility, binding affinity and sequence specificity of PNAs are provided.
Patent JP-3553929-B2 (JP)
IPC: G02B6/12
Filed: 1991-05-21
Granted: 2004-08-11
Abstract: PCT No. PCT/GB91/00795 Sec. 371 Date Dec. 18, 1992 Sec. 102(e) Date Dec. 18, 1992 PCT Filed May 21, 1991 PCT Pub. No. WO91/18304 PCT Pub. Date Nov. 28, 1991.There are disclosed variations on a basic technique for forming a diffusion or rear-projection screen comprising an array of microlenses formed by selective light exposure and consequent selective polymerization of a sheet of photopolymerizable material. Thus, the lenses may be made elongate in a preferred direction transverse to the lens axes by exposure through a mesh formed with an array of slots. The lenses may be graded refractive index lenses having a surface relief adding to the lens power, such relief being formed naturally or by molding. The photopolymerizable material may be exposed by laser light, for example to a holographic pattern and such exposure may be made through a quarter-wave plate continuously rotated to eliminate micro defects. Enhanced lens powers may be achieved by heating the photopolymerizable material to close to the softening temperature of the associated polymer before exposure to light and maintaining the material at that temperature during the resultant polymerization.
Patent JP-3091222-B2 (JP)
IPC: H01L21/60
Filed: 1991-07-16
Granted: 2000-09-25
Abstract: PCT No. PCT/GB91/01172 Sec. 371 Date Mar. 18, 1993 Sec. 102(e) Date Mar. 18, 1993 PCT Filed Jul. 16, 1991 PCT Pub. No. WO92/02038 PCT Pub. Date Feb. 6, 1992.Uniaxially conductive connector formed in situ on microchip by laser drilling an insulating layer at least 5 micrometers thick to provide holes communicating with the chip bonding sites, and depositing metal in the holes to establish electrical connection with the bonding sites. Excimer U.V. laser ablation of a polyimide insulating layer is preferred, followed by removal of a surface layer (preferably of amorphous polyamide from the insulating layer to expose the ends of the metal deposited in the holes.
Patent JP-3565864-B2 (JP)
IPC: C07D401/14
Filed: 1997-09-11
Granted: 2004-09-15
Abstract: This invention is directed to benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity.
Patent JP-2823693-B2 (JP)
IPC: A61F9/00
Filed: 1993-03-12
Granted: 1998-11-11
Abstract: A cartridge for actuating a piston-like or accordion-like dispenser-vial for applying medicament to an eye. The cartridge includes a housing for holding the dispenser-vial and a telescoping cylinder for compressing the dispenser-vial in the longitudinal direction to actuate the vial. The cartridge includes a locking mechanism for locking the telescoping cylinder to restrict its movement and a trigger mechanism for releasing the cylinder from the locked position so that a drop is released from the dispenser. The housing includes a finger for engaging the lower eyelid and exposing the conjunctival cul de sac.
Patent JP-4338217-B2 (JP)
IPC: A61K31/44
Filed: 1997-02-12
Granted: 2009-10-07
Abstract: The present invention relates to novel optionally substituted 8-cyano-1-cyclo-propyl-7-(2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids and their derivatives, of the general formula (I)in whichR1 represents hydrogen, C1-C4-alkyl which is optionally substituted by hydroxyl, methoxy, amino, methylamino or dimethylamino, or (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl,R2 represents hydrogen, benzyl, C1-C3-alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, radicals having the structures -CH=CH-COOR3, -CH2CH2COOR3, -CH2CH2CN, -CH2CH2COCH3 or -CH2COCH3, in which R3 represents methyl or ethyl, or a radical of the general structure R4-(NH-CHR5-CO)n-, in which R4 represents hydrogen, C1-C3-alkyl or the radical -COO-tert-butyl, R5 represents hydrogen, C1-C4-alkyl, hydroxyalkyl, aminoalkyl, thioalkyl, carboxyalkyl or benzyl and n is 1 or 2, andY is oxygen or sulfur,the process for their preparation and their use in antibacterial compositions.
Patent PL-155524-B2 (PL)
IPC: G06F/
Filed: 1987-03-17
Abstract: Układ podstawowej jednostki inteligencji, zawierający
układ wejścia-wyjścia, jednostkę centralną w postaci
procesora oraz pamięć stałą i pamięć operacyjną, spośród
których układ wejścia-wyjścia stanowi połączenie
wewnętrznych magistral z otoczeniem, a magistrala
wewnętrzna danych, sterująca i adresowa są przyłączone
do procesora, do pamięci stałej i do pamięci operacyjnej,
znamienny tym, że układ wejścia-wyjścia zestawiony jest z
dwóch niezależnych buforów (1/01) i (1/02), przyłączonych
do magistrali sterującej (MSI), magistrali danych
(MDI) i magistrali adresowej (MAI), poprzez multiplekser
(ΜΡΧ), przy czym bufor (1/02) układu wejściawyjścia
przyłączony jest do buforu (1/0) wejścia-wyjścia
układu próbkowania i formowania programu (PFP),
składającego się z jednostki centralnej (MP2), pamięci
stałej (ROM2) oraz pamięci operacyjnej (RAM2), połączonych
wspólnie wewnętrzną magistralą danych (MD2),
wewnętrzną magistralą sterującą (MS2) oraz wewnętrzną
magistralą adresową (MA2), przy pomocy których jest do
niego przyłączona dodatkowa pamięć operacyjna
(RAM3) oraz sterowany generator liczb losowych (GLL),
zaś bufor (1/0) wejścia-wyjścia układu próbkowania i
formowania programu (PFP) przyłączony jest do układu
kontroli gramatycznej poprawności programu (CU),
stanowiącego zwłaszcza oprogramowany komputer,...
Patent ES-2249146-B2 (ES)
Title: Sistema de posicionamiento y anclaje de utiles y herramientas a maquinas-herramienta.
Inventor: VILLAGRASA FERRER FRANCISCO
IPC: B23B29/24
Filed: 2004-06-29
Granted: 2007-02-16
Abstract: Sistema de posicionamiento y anclaje de útiles y
herramientas a máquinas-herramienta, que comprende
los rebajes (2) practicados en el disco (1) presentando una de sus
caras (3) definida por dos superficies rectas convergentes hacia el
exterior, y en uno de los vértices de su cara interna, a ambos
lados, un cajeado (9); el cuerpo de cuña (8) que presenta una de sus
caras (11) definida por dos superficies rectas convergentes hacia el
exterior, mientras que su cara (12) opuesta, presenta, al menos, un
saliente (13) en posición inclinada; el
porta-herramientas (7) que presenta en la cara de
acoplamiento al cuerpo de cuña, al menos, un saliente (15) en
posición inclinada y en una cara ortogonal a aquella presenta un
saliente (16) según toda su longitud; el husillo (10) de fijación
del correspondiente porta-herramientas (7) a la
unidad de posicionamiento y anclaje que presenta un roscado (18) y
(19) doble a izquierda y derecha.
Patent ES-2427719-B2 (ES)
Title: Cabezal de corte para maquinas de corte.
Inventor: GONZALEZ GARCIA EMILIO
IPC: B23K7/10
Filed: 2012-04-27
Granted: 2014-10-13
Abstract: Cabezal de corte para máquinas de corte.#Especialmente concebido para ser implantado en máquinas de corte, es decir para máquinas destinadas al corte de chapa con bordes achaflanados, la invención permite obtener un cabezal estructuralmente simple, pero a la vez sumamente preciso, evitando posibles desajustes del dispositivo. Para ello, el mismo está constituido a partir de una carcasa, dotada de medios de sujeción articulada del cabezal de corte (6), respecto de un eje perpendicular al eje longitudinal de la carcasa, estando dicho cabezal asociado a una transmisión accionadas mediante un primer motor (9) que se fija en el seno de la carcasa del cabezal.#Perpendicularmente a este primer motor (9) se dispone un segundo motor (12) que acciona una reductora (14), asociada a los medios de fijación (15) del cabezal, definiendo un eje de giro para el cabezal ortogonal al eje de giro del cabezal de corte. En el seno de la carcasa se define una cámara (17) con una ventana inferior (18), con su correspondiente tapa láser (19), cámara en la que está destinado a implantarse un sensor láser (20) de medición, con su correspondiente cilindro láser (21).
Patent AU-2001258102-B2 (AU)
Title: Immunogenic polypeptides encoded by mage minigenes and uses thereof
Inventor: BERINSTEIN NEIL
IPC: C12N15/12
Filed: 2001-05-07
Granted: 2007-03-01
Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.
Patent AU-2001270560-B2 (AU)
Title: Phenyl-substituted 5,6-dihydropyrone derivatives for use as pesticides and herbicides
Inventor: LIEB FOLKER
IPC: C07D309/32
Filed: 2001-06-08
Granted: 2006-03-09
Abstract: The present invention relates to novel phenyl-substituted 5,6-dihydro-pyrone derivatives of the formula (I) in which W, X, Y, Z, G, A, B, Q<SUP>1 </SUP>and Q<SUP>2 </SUP>are each as defined in the description, to a plurality of processes for their preparation and to their use as pesticides and herbicides.
Patent AU-2002237517-B2 (AU)
Title: Biotin-derivatives and their conjugates with chelating agents
Inventor: CHINOL MARCO
IPC: C07D495/04
Filed: 2002-02-15
Granted: 2006-11-30
Abstract: Formula (I) compounds are described where the groups are as defined here below, processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particularly for the diagnosis and therapy of pathological conditions such as tumours.
Patent AU-2002252184-B2 (AU)
Title: Novel inhibitors of formation of advanced glycation endproducts (AGEs)
Inventor: LALEZARI IRAJ
IPC: A61P31/10
Filed: 2002-03-06
Granted: 2006-11-30
Abstract: The nonenzymatic glycation and crosslinking of proteins is a part of the aging process with the glycation endproducts and crosslinking of long-lived proteins increasing with age. This process is increased at elevated concentrations of reducing sugars in the blood and in the intracellular environment such as occurs with diabetes. The structural and functional integrity of the affected molecules become perturbed by these modifications and can result in severe consequences. The compounds of the present invention can be used to inhibit this process of nonenzymatic glycation and therefore to inhibit some of the ill effects caused by diabetes or by aging. The compounds are also useful for preventing premature aging, spoilage of proteins in food and can prevent discoloration of teeth.
Patent AU-2002322449-B2 (AU)
Title: Stabilized bromine solutions, method of making and uses thereof for biofouling control
Inventor: COLLIAS GEORGE J
IPC: C11D11/00
Filed: 2002-07-10
Granted: 2008-06-05
Abstract: Stabilized bromine solutions are prepared by combining a bromine source and a stabilizer to form a mixture, and then adding an oxidizer to the mixture.
Patent AU-2003204942-B2 (AU)
Title: A selective deleukocytation unit for a platelet product
Inventor: VERPOORT THIERRY
IPC: A61M1/36
Filed: 2003-06-25
Granted: 2008-04-10
Abstract: Filtration unit comprises external enclosure with inlet orifice(s) and outlet orifice(s), and a porous element enclosed by the external enclosure and having deleukocytation medium. The deleukocytation medium has non-woven, porous polyurethane fabric layer. The filtration unit is operable to leukodeplete a fluid having leukocytes and platelets when the fluid flows from upstream to downstream via the filtration unit.  Independent claims are also included for: (a) bag system comprising a collection bag for receiving a fluid containing platelets and having an outlet orifice, a filtration unit (1), a filtrate collection bag, a tube for providing connection from the outlet orifice of the collection bag to the inlet orifice (3) of the filtration unit, and a tube for providing connection between the outlet orifice (4) of the filtration unit and the inlet orifice of the filtrate collection bag; (b) fluid filter material comprising gas plasma-treated polyurethane; and (c) method for treating a polyurethane filter material comprising exposing the filter material to a gas plasma to increase the hydrophilicity of the filter material.
Patent AU-2003255290-B2 (AU)
Title: Use of erythropoietin
Inventor: HALLER HERMANN
IPC: A61K38/19
Filed: 2003-07-25
Granted: 2009-04-09
Abstract: Use of erythropoetin (EPO) and/or its derivatives for stimulating, in endothelial precursor cells (EPC), any of physiological mobilization; proliferation; differentiation to endothelial cells and/or migration, in the direction of an angiogenic or vasculogenic stimulus. Independent claims are also included for the following: (1) use of EPO and/or its derivatives for stimulating formation of endothelial cells (EC) and/or for vasculogenesis; (2) use of EPO to produce a transplantable EC product; (3) use of EPO for treating a tissue or organ transplant; (4) use of EPO for pretreatment of tissue or organ transplants; (5) use of EPO to prepare implantable or transplantable, cell-containing in vitro organ or tissue systems; (6) use of EPO for coating vascular prostheses or heart valves; and (7) pharmaceutical composition containing (a) EPO, its derivatives, analogs, modifications or muteins and (b) at least one of vascular endothelial growth factor, PIGF (not defined), granulocyte-macrophage colony-stimulating factor and/or a hydroxymethyl glutarate-CoA reductase inhibitor. ACTIVITY : Antilipemic; Antidiabetic; Antiinflammatory; Antiarteriosclerosis; Cardiant; Vasotropic; Antianginal; Gynecological; Hypotensive; Nephrotropic. No details of tests for any of these activities are given. MECHANISM OF ACTION : Treatment with EPO increases adhesion of EPC and stimulates formation of endothelial tissue and blood vessels.
Patent AU-2003257653-B2 (AU)
Title: Non-Aqueous secondary battery and separator used therefor
Inventor: HONMOTO HIROYUKI
IPC: H01M50/449
Filed: 2003-08-21
Granted: 2008-11-13
Abstract: A non-aqueous secondary battery separator composed of a porous film made of an organic polymer, which includes a network-like support, swells in the electrolyte solution and retains the electrolyte solution, wherein the network-like support has a mean film thickness of 10-30  mu m, a basis weight of 6-20 g/m<2>, a Gurley value of no greater than 10 sec/100 cc, a McMullin number (25 DEG C) of no greater than 10 and a (McMullin number x mean film thickness ( mu m)) product of no greater than 200  mu m, and the separator has a mean film thickness of 10-35  mu m, a basis weight of 10-25 g/m<2> and a Gurley value of no greater than 60 sec/100 cc, or exceeding 60 sec/100 cc and no greater than 500 sec/100 cc. Both battery characteristics and safety are achieved by establishing a specific electrochemical relationship between the effective active substance content of the battery system and the overcharge-preventing function characteristic values. <IMAGE>
Patent AU-2003260019-B2 (AU)
Title: Device and method for percutaneous placement of lumbar pedicle screws and connecting rods
Inventor: BOEHM FRANK H JR
IPC: A61B17/70
Filed: 2003-08-21
Granted: 2008-04-24
Abstract: A spinal surgical system comprising a dilator (28) and a tissue cutting instrument (26), wherein said dilator is provided with a recess (30) and wherein said tissue cutting instrument is deployable through the dilator. The tissue cutting instrument is provided with a blade (34) that is pivotable between an extended deployed position, wherein the blade extends through the recess of the dilator, and a retracted rest position, wherein the blade is withdrawn into the dilator.
Patent AU-2004229418-B2 (AU)
Title: Compounds for the treatment of metabolic disorders
Inventor: BORSTEL REID W VON
IPC: A61K/
Filed: 2004-04-08
Granted: 2008-07-31
Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R2 is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R1 is not hydrogen. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula I.
Patent AU-2004273099-B2 (AU)
Title: Method and device for generating alfven waves
Inventor: FRISCHAUF NORBERT
IPC: H05H1/54
Filed: 2004-09-15
Granted: 2009-09-24
Abstract: The invention relates to a method and a device for generating Alfvén waves, in which ionizable material is provided that penetrates a magnetic field. In order to create such a method or a device in which material can be conveyed based on the Alfvén waves, the magnetic field consists of a primary magnetic field that is periodically deformed by at least one oscillating secondary magnetic field that is polarized in the opposite direction from the primary field such that Alfvén waves are created in the ionizable material located in said magnetic field. The Alfvén waves propagate at a speed that depends on the density of the material penetrating the magnetic field and the field intensity of the magnetic field. The field intensity of the magnetic field is greater than the kinetic energy of the material located in the magnetic field such that material is conveyed by means of the Alfvén waves.